CHICAGO: Patients with advanced multiple myeloma treated with bluebird bio’s experimental immunotherapy lived for a median of nearly a year before their cancer worsened, according to data from a small study presented on Friday. The treatment, called bb2121, belongs to a hot new therapy class called CAR-T that harvests a patient’s own disease-fighting T-cells, genetically modifies them in...Continue Reading
PHYSICAL ADDRESS
Floor 7, 90 The Terrace
Wellington Central
New Zealand